(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
19 June 2025 (19.06.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/125137 A1

(51) International Patent Classification:
A61P 35/00 (2006.01) *C07K 16/28* (2006.01)
A61P 37/00 (2006.01)

(21) International Application Number:
PCT/EP2024/085230

(22) International Filing Date:
09 December 2024 (09.12.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/608,374 11 December 2023 (11.12.2023) US

(71) Applicant: **GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED** [GB/GB]; GSK Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY (GB).

(72) Inventors: **AHMED, Farheen**; GSK, GSK Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY (GB). **ORECCHIA, Martin**; GSK, GSK Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY (GB). **OVECKA, Milan**; c/o GSK, GSK Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY (GB).

(74) Agent: **SHEPHERD, Marianne**; GSK, Legal & Compliance - Global Patents, 79 New Oxford Street, London WC1A 1DG (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

WO 2025/125137 A1

(54) Title: BAFF SPECIFIC ANTIBODIES

(57) Abstract: The present invention relates to anti-BLyS antigen binding proteins such as an anti-BLyS antibody which is capable of antagonizing BLyS. The invention also relates to nucleic acid sequences which encode the antigen binding protein as well as the use the antigen binding protein in therapy, for example, in diseases in which B cells play a pathogenic role, such as, for example, in autoimmune diseases, chronic inflammatory diseases and/or cancer.